Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Yahoo! Finance
R&D Expenses: Decreased in Q3 2024 compared to the prior year, primarily due to lower COVID-19 spending, offset by higher HCV Phase 2 trial spending. G&A Expenses: Decreased in Q3 2024 compared to the corresponding period in 2023, mainly due to lower professional fees. Interest Income: Decreased in Q3 2024 compared to the prior year due to lower investment balances. Cash Runway: Projected to extend well into 2027. Warning! GuruFocus has detected 2 Warning Sign with AVIR. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Atea Pharmaceuticals Inc ( NASDAQ:AVIR ) has executed two large global clinical programs on time and on budget. The company is on track to report top line results from its Phase 2 HCV study in early December. Atea Pharmaceuticals Inc ( NASDAQ:AVIR ) has a strong financial position with $492.8 million in cash, cash equivalents, and marketable securities as of September 3
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024GlobeNewswire
- Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024GlobeNewswire
- Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024GlobeNewswire
AVIR
Earnings
- 11/7/24 - Beat
AVIR
Sec Filings
- 11/20/24 - Form EFFECT
- 11/15/24 - Form SC
- 11/12/24 - Form SC
- AVIR's page on the SEC website